To read the full story, subscribe or sign in.

Hengrui's innovation paying off in largest out-licensing deal to date for China biotech

Sep. 4, 2015

By Shannon Ellis

SHANGHAI – Drug developers in China just received a strong signal that homegrown innovation can be very lucrative.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for July 3, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 3, 2025.

AI-generated illustration of CAR T cells

Researchers arm CAR T cells to fight solid tumors

BioWorld

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...

Bioversys, Shionogi in CHF529M lung infection collaboration

BioWorld Science

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...

Medtronic receives CE mark for its Vitalflow ECMO system

BioWorld MedTech

Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...